XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.
Rectal Neoplasms|Locally Advanced Rectal Adenocarcinoma
DRUG: bevacizumab
Pathologic Complete Response Rate, after concomitant CT-RT treatment
Complete Resection (R0) Rate, after surgery|Disease Free Survival, from complete response to relapse or disease-related death|Time to Failure Treatment, from first treatment dose to drop out of the study|Metastatic or Local Recurrence, during study|Toxicity Evaluation, during study|Surgical Morbility, during surgery
The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.